Effect of strontium ranelate on vertebral pain syndrome in postmenopausal women with systemic osteoporosis treatment
Vladyslav Povoroznyuk, Nataliia Dzerovych & Tetyana Orlyk
Aim: To evaluate the effect of strontium ranelate in treatment of systemic osteoporosis in postmenopausal women.
Materials and methods: There were examined 82 postmenopausal women with systemic osteoporosis (average age 58.4±4.5 years). Evaluation of pain syndrome and level of physical activity was carried out with VAS (the questionnaire developed by the Servier company). Bone mineral density (BMD) was determined by means of dual-energy X-ray absorptiometer Prodigy (GE Medical systems) in 18 patients (average age 61.2±1.8 years). Examination was performed before onset of treatment and after a 3 and 6 months treatment course. Strontium ranelate (Bivalos, Servier) was taken in a dose of one 2 g sachet as a suspension in water once a day and one tablet of calcemin-advance (Calcium 500 mg, Vit. D 400 IU) two times a day during 6 months.
Results: We observed a reliable decrease of vertebral pain syndrome after three (from 9.06±1.44 up to 5.67±0.34; t=1.93; P=0.06) and six months (from 8.52±1.32 up to 4.66±0.32; t=2.88; P=0.005) and increase of functional abilities of patients after three (from 6.59±0.33 up to 5.85±0.34; t=3.94; P=0.0002) and 6 months (from 6.80±0.34 up to 4.97±0.36; t=6.91; P<0.0001). The patients have noted that their sleeping improved after three (from 5.70±0.37 up to 4.91±0.35; t=3.16; P=0.002) and 6 (from 0.39±3.32 up to 3.46±0.36; t=7.29; P<0.0001) months. The fear of fractures occurrence has decreased significantly after three (from 7.72±0.34 up to 7.05±0.37; t=3.19; P=0.002) and 6 (from 7.81±0.35 up to 6.62±0.43; t=4.10; P=0.0001) months. After six months, BMD of femur (total) significantly increased in comparison with indexes before treatment (BMD of femur before treatment 0.79±0.02; after 6 months 0.81±0.02; t=−2.49; P=0.03).
Conclusion: It has been demonstrated that strontium ranelate treatment significantly decreases pronounced vertebral pain syndrome and improves functional abilities of patients, as well as BMD of femur after six-month therapy in the postmenopausal women.